Wilson Disease

CONTINUUM Lifelong Learning in Neurology

Volumn 22, Issue 4,MovementDisorders, 2016, Pages 1246-1261

  Pfeiffer, Ronald F ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CERULOPLASMIN; COPPER; PENICILLAMINE; TRIENTINE; TETRATHIOMOLYBDIC ACID; ZINC;

ABSORPTION; BRAIN DEPTH STIMULATION; CHELATION THERAPY; CLINICAL FEATURE; COPPER BLOOD LEVEL; DIAGNOSTIC TEST; DIET THERAPY; EYE DISEASE; GENETIC SCREENING; HUMAN; INTESTINE; LIVER BIOPSY; LIVER DISEASE; LIVER TRANSPLANTATION; MENTAL DISEASE; NEUROIMAGING; NEUROLOGIC DISEASE; PRACTICE GUIDELINE; REVIEW; SLIT LAMP; URINARY EXCRETION; WILSON DISEASE; ACUTE HEPATITIS; ASCITES; AUTONOMIC DYSFUNCTION; CERULOPLASMIN BLOOD LEVEL; DEPRESSION; DIAGNOSTIC ERROR; DIFFERENTIAL DIAGNOSIS; DYSPHAGIA; ESOPHAGUS VARICES; FRACTURE; FULMINANT HEPATIC FAILURE; HEADACHE; HEMOLYTIC ANEMIA; LIVER CIRRHOSIS; LIVER DYSFUNCTION; OSTEOPOROSIS; PARANOIA; PATIENT MONITORING; SEIZURE; SLIT LAMP MICROSCOPY; SPLENOMEGALY; SUICIDAL BEHAVIOR; URINE LEVEL; COMPLICATION; GENETICS;

DIAGNOSIS, DIFFERENTIAL; GENETIC TESTING; HEPATOLENTICULAR DEGENERATION; HUMANS;

EID: 84982965890     PISSN: 10802371     EISSN: 15386899     Source Type: Journal    
DOI: 10.1212/CON.0000000000000350     Document Type: Review

References (40)

1. Wilson SAK. Progressive lenticular degeneration: A familial nervous system disease. Br Med J 1912;2(2710):1645.
2. Lutsenko S. Modifying factors and phenotypic diversity in Wilsons disease. Ann N Y Acad Sci 2014;1315:56-63. doi:10.1111/nyas.12420.
3. Dusek P, Roos PM, Litwin T, et al. The neurotoxicity of iron, copper and manganese in Parkinsons and Wilsons diseases. J Trace Elem Med Biol 2015;31: 193-203. doi:10.1016/j.jtemb.2014.05.007.
4. Ranucci G, Socha P, Iorio R. Wilson disease: what is still unclear in pediatric patients? Clin Res Hepatol Gastroenterol 2014;38(3): 268-272. doi:10.1016/j.clinre.2014.03.002.
5. Bandmann O, Weiss KH, Kaler SG. Wilsons disease and other neurological copper disorders. Lancet Neurol 2015;14(1):103-113. doi:10.1016/S1474-4422(14)70190-5.
6. Ferenci P. Phenotype-genotype correlations in patients with Wilsons disease. Ann N Y Acad Sci 2014;1315:1-5. doi:10.1111/nyas.12340.
7. Coffey AJ, Durkie M, Hague S, et al. A genetic study of Wilsons disease in the United Kingdom. Brain 2013;136(pt 5): 1476-1487. doi:10.1093/brain/awt035.
8. Olivarez L, Caggana M, Pass KA, et al. Estimate of the frequency of Wilsons disease in the US Caucasian population: A mutation analysis approach. Ann Hum Genet 2001;65(pt 5):459-463. doi:10.1017/S0003480001008764.
9. Ferenci P, Caca K, Loudianos G, et al. Diagnosis and phenotypic classification of Wilson disease. Liver Int 2003;23(3):139-142. doi:10.1034/j.1600-0676.2003.00824.x.
10. Aggarwal A, Aggarwal N, Nagral A, et al. A novel global assessment scale for Wilsons disease (GAS for WD). Mov Disord 2009;24(4):509-518. doi:10.1002/mds.22231.
11. Członkowska A, Tarnacka B, Möller JC, et al. Unified Wilsons Disease Rating ScaleVa proposal for the neurological scoring of Wilsons disease patients. Neurol Neurochir Pol 2007;41(1):1-12.
12. Brewer GJ. Wilsons disease: A clinicians guide to recognition, diagnosis, and management. Boston, MA: Kluwer, 2001.
13. Merle U, Schaefer M, Ferenci P, Stremmel W. Clinical presentation, diagnosis, and long-Term outcome of Wilsons disease: A cohort study. Gut 2007;56(1):115-120. doi:10.1136/gut.2005.087262.
14. Kim JW, Kim JH, Seo JK, et al. Genetically confirmed Wilson disease in a 9-month old boy with elevations of aminotransferases. World J Hepatol 2013;5(3):156-159. doi:10.4254/wjh.v5.i3.156.
15. Członkowska A, Rodo M, Gromadzka G. Late onset Wilsons disease: Therapeutic implications. Mov Disord 2008;23(6): 896-898. doi:10.1002/mds.21985.
16. Schilsky ML. Liver transplantation for Wilsons disease. Ann N Y Acad Sci 2014;1315:45-49. doi:10.1111/nyas.12454.
17. Ala A, Borjigin J, Rochwarger A, Schilsky M. Wilson disease in septuagenarian siblings: raising the bar for diagnosis. Hepatology 2005;41(3):668-670. doi:10.1002/hep.20601.
18. Machado A, Chien HF, Deguti MM, et al. Neurological manifestations in Wilsons disease: report of 119 cases. Mov Disord 2006;21(12):2192-2196. doi:10.1002/mds.21170.
19. Dusek P, Litwin T, Czlonkowska A. Wilson disease and other neurodegenerations with metal accumulations. Neurol Clin 2015;33(1):175-204. doi:10.1016/j.ncl.2014.09.006.
20. Taly AB, Meenakshi-Sundaram S, Sinha S, et al. Wilson disease: description of 282 patients evaluated over 3 decades. Medicine (Baltimore) 2007;86(2):112-121. doi:10.1097/MD.0b013e318045a00e.
21. Berger B, Mader I, Damjanovic K, et al. Epileptic status immediately after initiation of D-penicillamine therapy in a patient with Wilsons disease. Clin Neurol Neurosurg 2014;127:122-124. doi:10.1016/j.clineuro.2014.09.030.
22. Zimbrean PC, Schilsky ML. Psychiatric aspects of Wilsons disease: A review. Gen Hosp Psychiatry 2014;36(1):53-62. doi:10.1016/j.genhosppsych.2013.08.007.
23. Basu A, Thanapal S, Sood M, Khandelwal SK. Catatonia: An unusual manifestation of Wilsons disease. J Neuropsychiatry Clin Neurosci 2015;27(1):72-73. doi:10.1176/appi.neuropsych.13120362.
24. Frota NA, Barbosa ER, Porto CS, et al. Cognitive impairment and magnetic resonance imaging correlations in Wilsons disease. Acta Neurol Scand 2013;127(6):391-398. doi:10.1111/ane.12037.
25. Roberts EA, Schilsky ML; American Association for Study of Liver Diseases (AASLD). Diagnosis and treatment of Wilson disease: An update. Hepatology 2008;47(6):2089-2111. doi:10.1002/hep.22261.
26. Roberts EA, Schilsky ML; Division of Gastroenterology and Nutrition, Hospital for Sick Children, Toronto, Ontario, Canada. A practice guideline on Wilson disease. Hepatology 2003;37(6):1475-1492. doi:10.1053/jhep.2003.50252.
27. Quemeneur AS, Trocello JM, Ea HK, et al. Bone status and fractures in 85 adults with Wilsons disease. Osteoporos Int 2014;25(11):2573-2580. doi:10.1007/s00198-014-2806-2.
28. Ferenci P, Steindl-Munda P, Vogel W, et al. Diagnostic value of quantitative hepatic copper determination in patients with Wilsons disease. Clin Gastroenterol Hepatol 2005;3(8):811-818. doi:10.1016/S1542-3565(05)00181-3.
29. McMillin GA, Travis JJ, Hunt JW. Direct measurement of free copper in serum or plasma ultrafiltrate. Am J Clin Pathol 2009;131(2):160-165. doi:10.1309/AJCP7Z9KBFINVGYF.
30. Sinha S, Taly AB, Ravishankar S, et al. Wilsons disease: cranial MRI observations and clinical correlation. Neuroradiology 2006;48(9):613-621. doi:10.1007/s00234-006-0101-4.
31. Hoogenraad TU. Paradigm shift in treatment of Wilsons disease: zinc therapy now treatment of choice. Brain Dev 2006;28(3): 141-146. doi:10.1016/j.braindev.2005.08.008.
32. Weiss KH, Gotthardt DN, Klemm D, et al. Zinc monotherapy is not as effective as chelating agents in treatment of Wilson disease. Gastroenterology 2011;140(4):1189-1198. e1. doi:10.1053/j.gastro.2010.12.034.
33. Aggarwal A, Bhatt M. The pragmatic treatment of Wilsons disease. Mov Disord Clin Pract 2014;1:14-23. doi:10.1002/mdc3.12003.
34. KozićDB, PetrovićI, Svetel M, et al. Reversible lesions in the brain parenchyma in Wilsons disease confirmed by magnetic resonance imaging: earlier administration of chelating therapy can reduce the damage to the brain. Neural Regen Res 2014;9(21):1912-1916. doi:10.4103/1673-5374.145360.
35. Weiss KH, Stremmel W. Clinical considerations for an effective medical therapy in Wilsons disease. Ann N Y Acad Sci 2014;1315:81-85. doi:10.1111/nyas.12437.
36. Litwin T, Dziezyc K, Karliński M, et al. Early neurological worsening in patients with Wilsons disease. J Neurol Sci 2015;355(1-2): 162-167. doi:10.1016/j.jns.2015.06.010.
37. Tian Y, Gong GZ, Yang X, Peng F. Diagnosis and management of fulminant Wilsons disease: A single centers experience.World J Pediatr 2016; 12(2):209-214. doi:10.1007/s12519-015-0026-2
38. Hedera P. Treatment of Wilsons disease motor complications with deep brain stimulation. Ann N Y Acad Sci 2014;1315:16-23. doi:10.1111/nyas.12372.
39. Annu A, Mohit B. Importance of adequate decoppering in Wilsons disease. Mov Disord 2014;29(8):1089. doi:10.1002/mds.25900.
40. Członkowska A, Litwin T, Karliński M, et al. D-penicillamine versus zinc sulfate as first-line therapy forWilsons disease. Ear J Neurol 2014;21(4):599-606. doi:10.1111/ene.12348.